These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 7933404)
41. [Disease modifying drugs in multiple sclerosis and pregnancy]. Tur C; Tintoré M; Aguilera C Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277 [No Abstract] [Full Text] [Related]
42. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients. Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926 [TBL] [Abstract][Full Text] [Related]
50. [Multiple sclerosis]. Itoyama Y No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536 [No Abstract] [Full Text] [Related]
51. Multiple sclerosis. Boggild M; Ford H Clin Evid; 2004 Dec; (12):1843-60. PubMed ID: 15865753 [No Abstract] [Full Text] [Related]
52. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542 [TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. Neuhaus O; Kieseier BC; Hartung HP J Neurol Sci; 2007 Aug; 259(1-2):27-37. PubMed ID: 17391705 [TBL] [Abstract][Full Text] [Related]
54. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
56. How should we proceed with disease-modifying treatments for multiple sclerosis? Andersson PB; Waubant E; Goodkin DE Lancet; 1997 Mar; 349(9052):586-7. PubMed ID: 9057726 [No Abstract] [Full Text] [Related]
57. Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis. Lage MJ; Castelli-Haley J; Oleen-Burkey MA Work; 2006; 27(2):143-51. PubMed ID: 16971761 [TBL] [Abstract][Full Text] [Related]
58. Anaphylactoid reaction to methyl prednisolone developing after starting treatment with interferon beta-1b. Clear D J Neurol Neurosurg Psychiatry; 1999 May; 66(5):690. PubMed ID: 10348645 [No Abstract] [Full Text] [Related]
59. No cash to implement NICE, health authorities tell MPs. The National Institute for Clinical Excellence. Burke K BMJ; 2002 Feb; 324(7332):258. PubMed ID: 11936127 [No Abstract] [Full Text] [Related]
60. PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. Baker DP; Pepinsky RB; Brickelmaier M; Gronke RS; Hu X; Olivier K; Lerner M; Miller L; Crossman M; Nestorov I; Subramanyam M; Hitchman S; Glick G; Richman S; Liu S; Zhu Y; Panzara MA; Davar G J Interferon Cytokine Res; 2010 Oct; 30(10):777-85. PubMed ID: 20836711 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]